Close Menu

cytogenetics

What will regulatory clearance mean for companies that manufacture chromosomal microarrays?

This article was originally posted on Feb. 1

By the end of next year, all of the large array vendors could have US Food and Drug Administration-cleared products on the market for postnatal constitutional cytogenetics.

Illumina's acquisition of BlueGnome has provided a boost for its array business.

SAN FRANCISCO — Illumina will not be the only array vendor submitting a cytogenetics-focused array to the US Food and Drug Administration for clearance this quarter.

Illumina CEO Jay Flatley provided an update on the company's array business at the JP Morgan Global Healthcare Conference in San Francisco this week.

Things are looking up for CombiMatrix. The Irvine, Calif.-based molecular diagnostics firm this week reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full year 2012, respectively.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

This article was originally posted on Dec. 6.
Several studies published last week in the New England Journal of Medicine underscore the rapidly shifting landscape for genomic tools in the diagnostic setting.

"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.

Pages

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.